PreveCeutical Medical Inc. (
CSE: C.PREV,
Forum) on Friday announced encouraging results the research and development project consisting of isolating and identifying peptides and proteins from Caribbean Blue Scorpion venom.
The company said the program consists of three distinct phases. Phase one, which is currently under way, involves one-dimensional gel electrophoresis to first identify scorpion venom-based peptides.
More information can be found
here.
PreveCeutical was in the news recently when the
company said it had signed a research and development agreement with UniQuest Pty Ltd. The agreement covers the extraction, formulation and Ex Vivo Evaluation of Cannabinoids for nose to brain delivery via Sol-Gels.
“Working with UniQuest and the University of Queensland on this research program provides PMI with unique opportunities towards developing products that promote good health and wellness,’’ said PMI Chairman and CEO Stephen Van Deventer.
FULL DISCLOSURE: PreveCeutical Medical Inc. is a paid client of Stockhouse Publishing.